{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:30:54Z","timestamp":1789381854704,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Herpes zoster (HZ) is an infectious disease caused by the reactivation of varicella zoster virus (VZV), with 68% of cases occurring in adults over 50 years of age. HZ\/su (Shingrix\u00ae) was approved by the Food and Drug Administration in 2017 for the prevention of HZ in individuals \u2265 50 years of age and showed very good protection from HZ. However, due to the use of the adjuvant AS01B, adverse reactions caused by Shingrix are a concern. Aluminum hydroxide is the most commonly used adjuvant and is widely used in a variety of vaccines. We developed a recombinant zoster vaccine (code: LZ901) consisting of a tetramer of VZV glycoprotein E (gE) and a human Fc fusion protein expressed in CHO cells, an immune complex-like molecule that can be adsorbed with an aluminum hydroxide adjuvant. We compared the immunogenicity of LZ901 with that of HZ\/su in BALB\/c mice. The results showed that LZ901 induced levels of gE-specific IgG antibodies comparable to those induced by HZ\/su, and the results of FAMA titers further demonstrated their similar neutralizing antibody abilities. Most importantly, LZ901 induced higher levels of cell-mediated immunity (CMI) (which plays a decisive role in the efficacy of zoster vaccines) than HZ\/su in BALB\/c mice. The numbers of cytokine-producing T cells in LZ901-vaccinated mice were significantly greater than those in v-vaccinated mice, and the proportions of CD4+ and CD8+ T cells producing at least two types of cytokines in LZ901-vaccinated mice were significantly greater than those in HZ\/su-vaccinated mice.<\/jats:p>","DOI":"10.3390\/vaccines12070775","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:17:32Z","timestamp":1721067452000},"page":"775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the Immunogenicity of the LZ901 Vaccine and HZ\/su Vaccine in a Mouse Model"],"prefix":"10.3390","volume":"12","author":[{"given":"Yaru","family":"Quan","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Luzhu Biotechnology Co., Ltd., Beijing 101100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Lu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Kong","sequence":"additional","affiliation":[{"name":"Beijing Luzhu Biotechnology Co., Ltd., Beijing 101100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Luzhu Biotechnology Co., Ltd., Beijing 101100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Kong","sequence":"additional","affiliation":[{"name":"Beijing Luzhu Biotechnology Co., Ltd., Beijing 101100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqin","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangwei","family":"Xu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[{"name":"Beijing Luzhu Biotechnology Co., Ltd., Beijing 101100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"Vroling","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e00305-19","DOI":"10.1128\/JVI.00305-19","article-title":"The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity","volume":"93","author":"Weinberg","year":"2019","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Clement","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dorrington, M.G., and Bowdish, D.M. (2013). Immunosenescence and novel vaccination strategies for the elderly. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00171"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2020.12.013","article-title":"Incidence and disease burden of herpes zoster in the population aged \u226550 years in China: Data from an integrated health care network","volume":"82","author":"Sun","year":"2021","journal-title":"J. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","unstructured":"Food and Drug Administration (2023, December 27). Shingrix [Package Insert], Revised: 07\/2021, Available online: https:\/\/www.fda.gov\/media\/108597\/download."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/infdis\/jiab580","article-title":"Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence","volume":"225","author":"Johnson","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liu, J., Lin, J., Cai, L., Sun, J., Ding, X., Wang, C., Wu, Y., Gao, X., Su, W., and Jiang, C. (2022). Immunogenicity of Varicella Zoster Virus DNA Vaccines Encoding Glycoprotein E and Immediate Early Protein 63 in Mice. Viruses, 14.","DOI":"10.3390\/v14061214"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/21505594.2022.2060464","article-title":"Glycosylation of viral proteins: Implication in virus-host interaction and virulence","volume":"13","author":"Feng","year":"2022","journal-title":"Virulence"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., and Yamanishi, K. (2007). VZV: Immunobiology and host response. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge University Press.","DOI":"10.1017\/CBO9780511545313"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","article-title":"Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence","volume":"130","author":"Williams","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4014\/jmb.1408.08048","article-title":"Measurement of antibodies to varicella-zoster virus using a virus-free fluorescent-antibody-to-membrane-antigen (FAMA) test","volume":"25","author":"Park","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pan, D., Wang, W., and Cheng, T. (2023). Current Methods for the Detection of Antibodies of Varicella-Zoster Virus: A Review. Microorganisms, 11.","DOI":"10.3390\/microorganisms11020519"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Komai-Koma, M., Ji, Y., Cao, H., Liu, Z., McSharry, C., and Xu, D. (2021). Monophosphoryl lipid A directly regulates Th1 cytokine production in human CD4+ T-cells through Toll-like receptor 2 and 4. Immunobiology, 226.","DOI":"10.1016\/j.imbio.2021.152132"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Junker, F., Gordon, J., and Qureshi, O. (2020). Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01393"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, P. (2021). Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines, 9.","DOI":"10.3390\/vaccines9030222"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: Putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review","volume":"60","year":"2019","journal-title":"Phytomedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39475","DOI":"10.1038\/srep39475","article-title":"Central Role of CD169+Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Welsby, I., Detienne, S., N\u2019Kuli, F., Thomas, S., Wouters, S., Bechtold, V., De Wit, D., Gineste, R., Reinheckel, T., and Elouahabi, A. (2017). Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00663"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.vaccine.2023.12.010","article-title":"Adjuvant AS01 activates human monocytes for co stimulation and systemic inflammation","volume":"42","author":"Smith","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:17:01Z","timestamp":1760109421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["vaccines12070775"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12070775","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}